Day One Biopharmaceuticals, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Revenues
Product revenue, net
License revenue
Total revenues
Operating expenses:
Cost of product revenue
Cost of license revenue
Research And Development Expense
Selling, general and administrative
Total cost and operating expenses
Loss from operations
Interest income (expense), net
Non-operating income:
Gain from sale of priority review voucher
Investment Income, Net
Other (expense) income, net
Changes in fair value of derivative tranche liability
Net loss attributable to redeemable convertible noncontrolling interests
Exchange of redeemable noncontrolling interest shares-deemed dividend
Net loss attributable to common stockholders/members
Net loss per share, basic and diluted
Weighted-average number of common shares used in computing net loss per share, basic and diluted
Total non-operating income, net
Loss before income taxes

Loss before income taxes
Income tax benefit (expense)
Net loss
Net loss per share, basic
Net loss per share, diluted
Weighted-average number of common shares used in computing net loss per share, basic
Weighted-average number of common shares used in computing net loss per share, diluted

Comments